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5: The ACCF/AHA/HRS and ECS recommend
dronedarone to decrease the risk of hospitalization for car-
diovascular causes; CCS does not. 
6: The ESC recommends angiotensin-converting enzyme
inhibitors and angiotensin-receptor blockers for AF preven-
tion; ACCF/AHA/HRS and CCS do not. 
7: The ACCF/AHA/HRS makes a class I recommendation
for catheter ablation in patients with paroxysmal AF who
fail a single antiarrhythmic drug; CCS and ESC make this a
class IIA recommendation. 
8: The ACCF/AHA/HRS and ECS recommend clopido-
grel plus aspirin for patients who refuse warfarin therapy;
CCS recommends dabigatran.  
9: The ACCF/AHA/HRS and CCS recommend the
CHADS2 score as a guide for stroke prevention; ESC rec-
ommends the CHA2DS2-VASc score.
Summary written by: Fred Morady, MD
Irbesartan in Patients With Atrial Fibrillation
The ACTIVE I Investigators.
N Engl J Med 2011;364:928-938. 
Study Question: What are the effects of irbesartan on the risk
of cardiovascular events and maintenance of sinus rhythm in
patients with atrial fibrillation? 
Methods: The investigators randomly assigned patients with a
history of risk factors for stroke and a systolic blood pressure
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Comparing the 2010 North American and European
Atrial Fibrillation Guidelines
Gillis AM, Skanes AC.
Can J Cardiol 2011;27:7-13.
Perspective: Nine differences in recommendations for man-
agement of atrial fibrillation between the American College
of Cardiology Foundation/American Heart
Association/Heart Rhythm Society (ACCF/AHA/HRS),
the Canadian Cardiovascular Society (CCS), and the
European Society of Cardiology (ESC) are: 
1: The CCS emphasizes treatment of comorbidities such as
hypertension and sleep apnea. 
2: The ESC recommends a resting heart rate target of <110
bpm for heart rate control, the ACCF/AHA/HRS recom-
mends this only if the ejection fraction is >40%, and the
CCS recommends <100 bpm. 
3: The CCS recommends atrioventricular junction ablation
(AVJA) for symptomatic patients with uncontrolled rates
despite drug therapy; ESC recommends AVJA for patients
with permanent AF who are candidates for cardiac resyn-
chronization therapy. 
4: The ACCF/AHA/HRS and ECS recommend avoidance
of class IC antiarrhythmic drugs and sotalol in patients with
left ventricular hypertrophy, while the CCS recommends
avoidance if there are repolarization abnormalities. 
Summaries of Key Journal Articles
Kim A. Eagle, MD, Editor-in-Chief, Journal Scan, Ann Arbor, MI
Christopher P. Cannon, MD, Editor-in-Chief, Cardiosource, Boston, MA
William F. Armstrong, MD, Ann Arbor, MI, David S. Bach, MD, Ann Arbor, MI, Ragavendra R.
Baliga, MBBS, Columbus, OH, Anna M. Booher, MD, Ann Arbor, MI, Timothy B. Cotts, MD, 
Ann Arbor, MI, Jennifer Cowger, MD, Ann Arbor, MI, Daniel T. Eitzman, MD, Ann Arbor, MI, 
James B. Froehlich, MD, Ann Arbor, MI, Caren S. Goldberg, MD, Ann Arbor, MI, Hitinder S. Gurm,
MBBS, Ann Arbor, MI, Jennifer C. Hirsch, MD, Ann Arbor, MI, Elizabeth Anne Jackson, MD, 
Ann Arbor, MI, Fred Morady, MD, Ann Arbor, MI, Debabrata Mukherjee, MD, El Paso, TX,
Himanshu J. Patel, MD, Ann Arbor, MI, John E. Rectenwald, MD, MS, Ann Arbor, MI, Melvyn
Rubenfire, MD, Ann Arbor, MI, Associate Editors, Cardiosource
SYNTAX study. In this large multicentric trial, 1,800
patients with three-vessel or left main coronary artery dis-
ease were randomized to undergo CABG or PCI with
paclitaxel-eluting stent. The Seattle Angina Questionnaire
(SAQ) and the Medical Outcomes Study 36-Item Short-
Form Health Survey (SF-36) were used to assess
health-related quality of life at baseline and at 1, 6, and 12
months. The primary endpoint was the score on the angina-
frequency subscale of the SAQ, with higher scores
corresponding to better health status. 
Results: Both revascularization strategies were associated with
significant improvement in quality of life at 6 and 12
months. There was no difference in freedom from angina at
1 month between PCI and CABG groups, whereas it was
slightly higher with CABG at 12 months (76.3% vs. 71.6%,
p = 0.05). CABG was associated with a greater increase in
the score on the angina-frequency subscale of the SAQ at 6
(p = 0.04) and 12 months (and p = 0.03), but this was driven
by small differences between the two groups (mean treat-
ment effect of 1.7 points at both time points). Scores on
almost all other SAQ and SF-36 subscales were higher with
PCI at 1 month and were similar at 6 months and beyond. 
Conclusions: Compared with PCI, CABG is associated with
greater relief from angina in patients with three-vessel or left
main coronary artery disease at 6 and 12 months.
Perspective: The 3-year follow-up from the SYNTAX trial
suggests that there is no difference in outcome with PCI or
CABG in patients with low SYNTAX score, while the out-
come is better with CABG in those with intermediate or
high SYNTAX scores (http://www.syntaxscore.com). Also,
both revascularization strategies are associated with an
improvement in quality of life. 
Summary written by: Hitinder S. Gurm, MBBS
General Cardiology
Diabetes Mellitus, Fasting Glucose, and Risk of
Cause-Specific Death
The Emerging Risk Factors Collaboration.
N Engl J Med 2011;364:829-841.
Study Question: What are the associations of baseline diabetes
and fasting blood glucose level with the risk of cause-specific
death? 
Methods: The investigators calculated hazard ratios for cause-
specific death, according to baseline diabetes status or fasting
glucose level, from individual participant data on 123,205
deaths among 820,900 people in 97 prospective studies. 
Results: After adjustment for age, sex, smoking status, and
body mass index, hazard ratios among persons with diabetes
versus without were: 1.80 (for death from any cause, 1.25 for
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of at least 110 mm Hg to receive either irbesartan at a target
dose of 300 mg once daily or double-blind placebo. These
patients were already enrolled in one of two trials (of clopi-
dogrel plus aspirin vs. aspirin alone or vs. oral
anticoagulants). The first coprimary outcome was stroke,
myocardial infarction, or death from vascular causes; the
second was the composite outcome plus hospitalization for
heart failure.
Results: A total of 9,016 patients were enrolled and followed
for a mean of 4.1 years. The mean reduction in systolic
blood pressure was 2.9 mm Hg greater in the irbesartan
group than placebo; the mean reduction in diastolic blood
pressure was 1.9 mm Hg greater. The first coprimary out-
come occurred at a rate of 5.4% per 100 person-years in
both groups (hazard ratio [HR] with irbesartan, 0.99). The
second coprimary outcome occurred at a rate of 7.3% per
100 person-years among patients receiving irbesartan and
7.7% for placebo (HR, 0.94). The rates of first hospitaliza-
tion for heart failure (a prespecified secondary outcome)
were 2.7% per 100 person-years with irbesartan, and 3.2%
with placebo (HR, 0.86). Among patients who were in sinus
rhythm at baseline, there was no benefit of irbesartan in
preventing hospitalization for atrial fibrillation. More
patients in the irbesartan group versus placebo had sympto-
matic hypotension (127 vs. 64) and renal dysfunction (43 vs.
24). 
Conclusions: Irbesartan did not reduce cardiovascular events
in patients with atrial fibrillation.
Perspective: The study suggests that among patients with atrial
fibrillation, irbesartan does not reduce the risk of death from
cardiovascular causes or this outcome plus hospitalization for
heart failure. Among patients in sinus rhythm at randomiza-
tion, there appears to be no effect on recurrence of atrial
fibrillation. Based on this, irbesartan should not be routinely
prescribed to patients with atrial fibrillation and well-con-
trolled hypertension. 
Summary written by: Debabrata Mukherjee, MD
Cardiovascular Surgery
Quality of Life After PCI With Drug-Eluting Stents
or Coronary-Artery Bypass Surgery
Cohen DJ, Van Hout B, Serruys PW, et al., on behalf of the
SYNTAX Investigators.
N Engl J Med 2011;364:1016-1026. 
Study Question: What is the relative improvement in quality
of life of patients undergoing coronary artery bypass surgery
(CABG) versus percutaneous coronary intervention (PCI)
with drug-eluting stents (DES)? 
Methods: The authors reported the quality of life data for the
mediate-risk categories without renal information vs. 18%
with renal information). 
Conclusions: In patients with high vascular risk, eGFR and
urinary albumin–creatinine ratio do not add much to tradi-
tional cardiovascular risk factors, but greatly improve risk
stratification for renal outcomes. 
Perspective: The utility of information on renal function for
predicting the study outcomes may differ in the general popu-
lation or in persons with renal disease, however. Further
research is needed on which patients at high risk for cardio-
vascular events might benefit from screening for low eGFR
and albuminuria and how their clinical management should be
modified on the basis of the results.
Summary written by: Debabrata Mukherjee, MD
Heart Failure/Transplant
Diuretic Strategies in Patients With Acute
Decompensated Heart Failure
Felker GM, Lee KL, Bull DA, et al., on behalf of the NHLBI Heart
Failure Clinical Research Network.
N Engl J Med 2011;364:797-805.
Study Question: How does intravenous furosemide given as a
bolus every 12 hours compare with continuous infusion and
at either a low or high dose in acute decompensated heart
failure (ADHF)? 
Methods: This was a prospective, double-blind, randomized
trial, where 308 patients with ADHF received furosemide
administered intravenously by means of either a bolus every
12 hours or continuous infusion and at either a low dose
(equivalent to patient’s previous oral dose) or high dose (2.5
times previous oral dose). Specified dose adjustments were
allowed after 48 hours. The patients’ global assessment of
symptoms (quantified as area under the curve [AUC] of the
score on a visual-analogue scale over 72 hours), and change
in the serum creatinine level from baseline to 72 hours were
coprimary endpoints. 
Results: When bolus administration was compared with con-
tinuous infusion, there was no significant difference in
patients’ global assessment of symptoms (mean AUC, 4236
± 1440 and 4373 ± 1404, respectively) or in the mean
change in the creatinine level (0.05 ± 0.3 mg/dl and 0.07 ±
0.3 mg/dl, respectively). When comparing the high-dose
with the low-dose strategy, there was a nonsignificant trend
toward greater improvement in patients’ global assessment
of symptoms in the high-dose group (mean AUC, 4430 ±
1401 vs. 4171 ± 1436). There was no significant difference
between these groups in the mean change in the creatinine
level (0.08 ± 0.3 mg/dl with the high-dose and 0.04 ± 0.3
mg/dl with the low-dose strategy). The high-dose strategy
death from cancer, 2.32 for death from vascular causes, and
1.73 for death from other causes. Diabetes (vs. no diabetes)
was moderately associated with death from cancers of the
liver, pancreas, ovary, colorectum, lung, bladder, and breast.
Diabetes (vs. no diabetes) was also associated with death
from renal disease, liver disease, pneumonia, and other
infectious diseases; mental disorders; nonhepatic digestive
diseases; external causes; intentional self-harm; nervous sys-
tem disorders; and chronic obstructive pulmonary disease.
Hazard ratios were appreciably reduced after further adjust-
ment for glycemia measures, but not after adjustment for
systolic blood pressure, lipid levels, inflammation, or renal
markers. Fasting glucose levels exceeding 100 mg/dl, but not
levels of 70-100 mg/dl, were associated with death. A 50-
year-old with diabetes died, on average, 6 years earlier than
a counterpart without diabetes, with about 40% of the dif-
ference in survival attributable to excess nonvascular deaths. 
Conclusions: Diabetes is associated with substantial premature
death from several cancers, infectious diseases, external causes,
intentional self-harm, and degenerative disorders. 
Perspective: These data show that diabetes is associated with
substantial premature mortality, independent of several
major risk factors. About 40% of the years of life lost from
diabetes can be attributed to nonvascular conditions, includ-
ing about 10% attributable to cancer. These findings
highlight the need to better understand and prevent the
multisystem consequences of diabetes.
Summary written by: Debabrata Mukherjee, MD
Estimated Glomerular Filtration Rate and
Albuminuria as Predictors of Outcomes in Patients
With High Cardiovascular Risk: A Cohort Study
Clase CM, Gao P, Tobe SW, et al.
Ann Intern Med 2011;154:310-318.
Study Question: What is the contribution of estimated glomeru-
lar filtration rate (eGFR) and urinary albumin–creatinine ratio
beyond that of traditional cardiovascular risk factors to classifi-
cation of patient risk for cardiovascular and renal outcomes? 
Methods: Lower eGFRs and higher urinary albumin–creati-
nine ratios were associated with the primary cardiovascular
composite outcome (for example, an adjusted hazard ratio of
2.53 for an eGFR <30 ml/min per 1.73 m2 and a very high
urinary albumin–creatinine ratio). However, adding infor-
mation about eGFR and urinary albumin–creatinine ratio to
the risk reclassification analyses led to no meaningful
decrease in the proportion of patients assigned to the inter-
mediate-risk category. In contrast, eGFR and urinary
albumin–creatinine ratio were strongly associated with risk
for long-term dialysis, and greatly improved both model cal-
ibration and risk stratification capacity when added to
traditional cardiovascular risk factors (65% assigned to inter-




was associated with greater diuresis and more favorable out-
comes in some secondary measures, but also with transient
worsening of renal function. 
Conclusions: There were no significant differences in symp-
toms or in the change in renal function when intravenous
furosemide therapy was administered by bolus compared
with continuous infusion, or at a high dose compared with a
low dose in patients with ADHF. 
Perspective: This study is important because it suggests that
the diuretic regimen or dose has little impact on symptoms
or renal function in ADHF. Evaluating the impact of any
therapy in ADHF is challenging because heart failure is
often accompanied by altered renal function. Further studies
are required to determine whether identifying the subtype of
cardiorenal syndrome in ADHF has better predictive value
in determining the response to the type of diuretic regimen.
Summary written by: Ragavendra R. Baliga, MBBS
Effectiveness of Cardiac Resynchronization
Therapy by QRS Morphology in the Multicenter
Automatic Defibrillator Implantation Trial–Cardiac
Resynchronization Therapy (MADIT-CRT)
Zareba W, Klein H, Cygankiewicz I, et al.
Circulation 2011;123:1061-1072.
Study Question: Is the response to cardiac resynchronization
therapy (CRT) affected by QRS morphology in patients
enrolled in the MADIT-CRT trial? 
Methods: The baseline electrocardiogram was analyzed in
1,817 patients (mean age 65 years) with cardiomyopathy, an
ejection fraction (EF) ≤30%, New York Heart Association
class I-II symptoms, and QRS duration ≥130 ms. Sixty per-
cent were randomly assigned to receive an implantable
cardioverter-defibrillator (ICD) with CRT (CRT-D), and
the remainder received an ICD. The mean follow-up was
29 months. The primary endpoint was a heart failure event
or death. 
Results: Seventy percent of patients had a left bundle branch
block (LBBB) and the remainder had a non-LBBB (right
bundle branch block [RBBB] in 13% and nonspecific inter-
ventricular conduction delay [IVCD] in 17%). In the LBBB
group, CRT-D therapy was associated with a 53% reduction
in the primary endpoint compared to ICD. There was not a
significant reduction in the primary endpoint with CRT-D
in the non-LBBB group. CRT was associated with a greater
reduction in left ventricular end-diastolic volume in patients
with LBBB (23%) than with non-LBBB (16%), and a
greater absolute improvement in EF (12% vs. 9%, respec-
tively). 
Conclusions: CRT-D therapy is associated with a significant
reduction in the risk of a heart failure event or death in
patients with an EF ≤30% and class I-II heart failure who
have an LBBB, but not in those who have a non-LBBB
QRS morphology. 
Perspective: The greater benefit of CRT in patients with
LBBB most likely reflects the greater degree of left ventricu-
lar dyssynchrony associated with LBBB than with RBBB or
nonspecific IVCD.
Summary written by: Fred Morady, MD
Left Ventricular Lead Position and Clinical Outcome
in the Multicenter Automatic Defibrillator
Implantation Trial–Cardiac Resynchronization
Therapy (MADIT-CRT) Trial
Singh JP, Klein HU, Huang DT, et al.
Circulation 2011;123:1159-1166.
Study Question: How important is the position of the left ven-
tricular (LV) lead in patients undergoing cardiac
resynchronization therapy (CRT)?  
Methods: This was a post-hoc analysis of 799 patients with
cardiomyopathy, ejection fraction ≤30%, New York Heart
Association class I-II heart failure (HF), and QRS ≥130 ms
who received CRT in the MADIT-CRT trial. The position
of the LV lead was documented by pre-implantation coro-
nary venous angiography and post-implantation chest
X-rays. The primary endpoint was death or HF. 
Results: In the short axis, the LV lead was positioned on the
lateral wall in 59%, the posterior wall in 22%, and the ante-
rior wall in 19% of patients. There were no significant
differences in HF or death between these lead positions. In
the long axis, the LV lead was midventricular in 63%, basal
in 23%, and apical in 14%. The prevalence of HF or death
was significantly higher when the lead was apical (21.8%)
than nonapical (13.3%). 
Conclusions: LV leads that are apical are associated with a
higher risk of HF or death in patients with mild HF undergo-
ing CRT. 
Perspective: In patients with a left bundle branch block, the
LV apex often is activated earlier than basal regions.
Placement of an LV lead for CRT in a region with the least
amount of delayed activation is expected to be less clinically
useful than when placed in basal regions of latest activation.
This probably explains why the apical lead position was
associated with worse outcomes in this study.
Summary written by: Fred Morady, MD
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Standard- vs High-Dose Clopidogrel Based on
Platelet Function Testing After Percutaneous
Coronary Intervention: The GRAVITAS Randomized
Trial
Price MJ, Berger PB, Teirstein PS, et al., on behalf of the
GRAVITAS Investigators.
JAMA 2011;305:1097-1105.
Study Question: Do patients with high on-treatment platelet
reactivity after percutaneous coronary intervention (PCI) derive
clinical benefit from high-dose clopidogrel?  
Methods: GRAVITAS is a randomized, double-blind, active-
control trial of 2,214 patients with high on-treatment
reactivity 12-24 hours after PCI with drug-eluting stents
(DES) receiving high-dose clopidogrel (600 mg initial dose,
150 mg daily thereafter) or standard-dose clopidogrel (no
additional loading dose, 75 mg daily) for 6 months. The pri-
mary endpoint was 6-month incidence of death from
cardiovascular causes, nonfatal myocardial infarction (MI), or
stent thrombosis. The key safety endpoint was severe or
moderate bleeding. 
Results: At 6 months, the primary endpoint had occurred in
2.3% receiving high-dose compared with 2.3% receiving
standard-dose clopidogrel (hazard ratio [HR], 1.01; p =
0.97). Severe or moderate bleeding was not increased with
the high-dose regimen (1.4% vs. 2.3%; HR, 0.59).
Compared with standard-dose, high-dose clopidogrel pro-
vided a 22% absolute reduction in the rate of high
on-treatment reactivity at 30 days (62 vs. 40%). 
Conclusions: Among patients with high on-treatment reactivity
after PCI with DES, the use of high-dose compared with
standard-dose clopidogrel did not reduce the incidence of
death from cardiovascular causes, nonfatal MI, or stent throm-
bosis.
Perspective: Previous studies have demonstrated that high
platelet reactivity, while on clopidogrel treatment, is associated
with a higher rate of adverse events following revascularization
procedures. Even though a higher dose of clopidogrel can
reduce this platelet reactivity, it has not been shown that this
will lead to a reduction in adverse vascular outcomes. Pending
additional clinical trials to test different treatment strategies,
the clinical utility of routine platelet function testing after PCI
remains dubious.
Summary written by: Daniel T. Eitzman, MD
Interventional
Permanent Pacemaker Insertion After CoreValve
Transcatheter Aortic Valve Implantation: Incidence
and Contributing Factors (the UK CoreValve
Collaborative)
Khawaja MZ, Rajani R, Cook A, et al.
Circulation 2011;123:951-960.
Study Question: What are the incidence and determinants of
permanent pacemaker (PPM) need in patients undergoing
transcatheter aortic valve implantation (TAVI) using
CoreValve? 
Methods: The authors evaluated the use of PPM in 270
patients undergoing CoreValve-based TAVI at 10 centers in
the United Kingdom.  
Results: The study population consisted of 243 patients after
excluding those with pre-existing pacemaker (n = 25) or those
with incomplete data (n = 2). QRS duration increased from
105 ± 23 to 135 ± 29 ms (p < 0.01), and a new left bundle
branch block developed in 56.8%. A PPM was required in
one third of patients in the first 30 days. Need for a pace-
maker varied based on pre-existing electrocardiogram (ECG)
abnormalities, with 65% of patients with a right bundle
branch block and 43% with a left bundle branch block need-
ing a PPM compared with 27% of those with a normal
baseline ECG. The median time to insertion was 4.0 days,
with nine patients undergoing PPM on the day of TAVI.
Independent predictors of PPM need were periprocedural
atrioventricular block (odds ratio [OR], 6.29), balloon predi-
latation (OR, 2.68), use of the larger (29 mm) CoreValve
prosthesis (OR, 2.50), interventricular septum diameter (OR,
1.18), and prolonged QRS duration (OR, 3.45; 95% CI,
1.61-7.40). 
Conclusions: PPM implantation is common in patients under-
going TAVI, especially in patients with pre-existing
conduction abnormalities. 
Perspective: The need for PPM is so common in patients
undergoing CoreValve TAVI that it should be considered a
consequence rather than a complication of the procedure.
This is likely related to the constant outward pressure
exerted by the nitinol frame of the valve and the resultant
impingement of the conduction system. This study provides
an easy tool to identify patients who are at risk for PPM,
and may be considered for prolonged observation after
TAVI.
Summary written by: Hitinder S. Gurm, MBBS





Preventing Weight Gain by Lifestyle Intervention in
a General Practice Setting: Three-Year Results of a
Randomized Controlled Trial
Ter Bogt NC, Bemelmans WJ, Beltman FW, Broer J, Smit AJ,
van der Meer K.
Arch Intern Med 2011;171:306-313.
Study Question: Can an intervention implemented in a general
office practice prevent weight gain among adults? 
Methods: This was a randomized controlled trial in 11 general
practice locations in the Netherlands. All patients included
had a body mass index (BMI) between 25 and 40 kg/m2 and
a diagnosis of hypertension and/or dyslipidemia. The inter-
vention group received lifestyle counseling from a nurse
practitioner (NP). Those in the control group received usual
care from their general practitioner (GP). The primary out-
come was body weight, waist circumference, blood pressure,
fasting glucose, and lipids after 3 years. 
Results: A total of 457 patients were included (mean age 56
years, 52% female). The dropout rate was 24% in the inter-
vention (NP) group and 20% in the usual care (GP) group.
In both groups, approximately 60% of participants achieved
weight maintenance after 3 years. The change in weight
over 3 years was -1.1 in the NP and -0.5 in the GP group.
There was no significant difference in mean weight change
or change in waist circumference. Fasting glucose was lower
among those in the NP (-0.02) compared with the GP
group (0.10). No difference between groups was observed
for changes in lipids or blood pressure. 
Conclusions: Lifestyle counseling by NPs did not result in sig-
nificant benefits in terms of weight maintained, waist
circumference, or other prevention efforts, including lipids and
blood pressure. In the majority of patients, lifestyle counseling
by providers or NPs resulted in prevention of weight gain. 
Perspective: This suggests that lifestyle counseling by GPs can
help patients prevent weight gain, and is equivalent to an
intervention by NPs. However, the majority of physicians do
not routinely counsel patients regarding lifestyle modification.
Summary written by: Elizabeth A. Jackson, MD
Olmesartan for the Delay or Prevention of
Microalbuminuria in Type 2 Diabetes
Haller H, Ito S, Izzo JL Jr, et al., on behalf of the ROADMAP Trial
Investigators.
N Engl J Med 2011;364: 907-917.
Study Question: What is the effect of treatment with olmesar-
tan on the occurrence of microalbuminuria in patients with
type 2 diabetes and normoalbuminuria? 
Methods: The investigators randomly assigned 4,447 patients
with type 2 diabetes to receive olmesartan (40 mg once daily)
or placebo for a median of 3.2 years. Additional antihyperten-
sive drugs (except angiotensin-converting enzyme inhibitors
or angiotensin-receptor blockers [ARBs]) were used as
needed to lower blood pressure to <130/80 mm Hg. The pri-
mary outcome was time to first onset of microalbuminuria.
Times to the onset of renal and cardiovascular events were
analyzed as secondary endpoints. 
Results: The target blood pressure (<130/80 mm Hg) was
achieved in nearly 80% of patients taking olmesartan and
71% taking placebo; blood pressure measured in the clinic
was lower by 3.1/1.9 mm Hg in the olmesartan group than
with placebo. Microalbuminuria developed in 8.2% of the
patients in the olmesartan group (178 of 2,160 patients who
could be evaluated) and 9.8% with placebo (210 of 2,139);
time to the onset of microalbuminuria was increased by
23% with olmesartan (hazard ratio for onset of microalbu-
minuria, 0.77). The serum creatinine level doubled in 1% of
the patients in each group. Slightly fewer patients in the
olmesartan group than placebo had nonfatal cardiovascular
events—81 of 2,232 (3.6%) compared with 91 of 2,215
patients (4.1%), but a greater number had fatal cardiovascu-
lar events—15 compared with 3 patients, a difference that
was attributable in part to a higher rate of death from car-
diovascular causes in the olmesartan than placebo group
among patients with pre-existing coronary heart disease
(2.0% vs. 0.2%). 
Conclusions: Olmesartan was associated with a delayed onset of
microalbuminuria. 
Perspective: The primary finding of this study is that ARB-
based therapy with olmesartan in patients with type 2
diabetes increased the time to the onset of microalbuminuria
by 23%. The overall rates of cardiovascular and cerebrovascu-
lar events were low, but there were more deaths from
cardiovascular causes in the olmesartan group than placebo.
An excessive reduction of blood pressure in some high-risk
patients may have conferred a predisposition to an increased
risk of death; however, a direct effect of olmesartan cannot be
ruled out and requires additional evaluation.
Summary written by: Debabrata Mukherjee, MD
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Antihypertensive Treatment and Secondary
Prevention of Cardiovascular Disease Events
Among Persons Without Hypertension: A Meta-
Analysis
Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J,
Bazzano LA.
JAMA 2011;305:913-922.
Study Question: Does treatment with antihypertensive medica-
tions among patients with a history of cardiovascular disease
(CVD), but not hypertension reduce the risk of death and
future CVD events? 
Methods: This was a meta-analysis of eligible studies identified
from MEDLINE (from 1950 to January 2011), EMBASE,
and the Cochrane Collaboration Central Register of
Controlled Clinical Trials, and manual examination of refer-
ences in selected articles. Studies were included if they were
randomized controlled trials of antihypertensive treatments
including patients with blood pressure <140 mm Hg systolic
and/or <90 mm Hg diastolic. A total of 874 papers were
identified, from which 25 trials met inclusion/exclusion crite-
ria. Information on participant characteristics, trial design and
duration, treatment drug, dose, control, and clinical events
was extracted using a standardized protocol. Outcomes
included stroke, myocardial infarction (MI), congestive heart
failure (CHF), composite CVD outcomes, CVD mortality,
and all-cause mortality.  
Results: Participants who received antihypertensive medica-
tions had a reduced risk for stroke (relative risk [RR], 0.77),
MI (RR, 0.80), CHF (RR, 0.71), and composite CVD
events (RR, 0.85) compared to controls. Both CVD mor-
tality (RR, 0.83) and all-cause mortality (RR, 0.87) were
also lower among participants on antihypertensive medica-
tions compared to controls. The corresponding absolute risk
reductions per 1,000 persons were −7.7 for stroke, −13.3 for
MI, −43.6 for CHF events, −27.1 for composite CVD
events, −15.4 for CVD mortality, and −13.7 for all-cause
mortality. Results did not differ according to trial character-
istics or subgroups defined by clinical history. 
Conclusions: Among patients with clinical history of CVD but
without hypertension, antihypertensive treatment was associ-
ated with decreased risk of stroke, CHF, composite CVD
events, and all-cause mortality. Additional randomized trial
data are necessary to assess these outcomes in patients without
CVD clinical recommendations. 
Perspective: This meta-analysis suggests that use of antihyper-
tensive therapies among patients with CVD can further
reduce events. As the authors suggest, prior to changes in
secondary prevention, randomized trials are warranted, partic-
ularly among diabetic patients.
Summary written by: Elizabeth A. Jackson, MD  
Long-Term Effects of Intensive Glucose Lowering
on Cardiovascular Outcomes
The ACCORD Study Group.
N Engl J Med 2011;364:818-828.
Study Question: What are the 5-year outcomes of intensive
glucose lowering on mortality and key cardiovascular events? 
Methods: The investigators randomly assigned participants
with type 2 diabetes and cardiovascular disease or additional
cardiovascular risk factors to receive intensive therapy (target-
ing a glycated hemoglobin below 6.0%) or standard therapy
(targeting a level of 7-7.9%). After termination of the inten-
sive therapy, due to higher mortality in the intensive-therapy
group, the target glycated hemoglobin level was 7-7.9% for
all participants, who were followed until the planned end of
the trial.  
Results: Before the intensive therapy was terminated, the
intensive-therapy group did not differ significantly from the
standard-therapy group in the rate of the primary outcome
(composite of nonfatal myocardial infarction, nonfatal
stroke, or death from cardiovascular causes) (p = 0.13), but
had more deaths from any cause (primarily cardiovascular)
(hazard ratio [HR], 1.21) and fewer nonfatal myocardial
infarctions (HR, 0.79). These trends persisted during the
entire follow-up period (HR for death, 1.19; and HR for
nonfatal myocardial infarction, 0.82). After the intensive
intervention was terminated, the median glycated hemoglo-
bin level in the intensive-therapy group rose from 6.4% to
7.2%, and the use of glucose-lowering medications and
rates of severe hypoglycemia and other adverse events were
similar in the two groups. 
Conclusions: Compared with standard therapy, the use of
intensive therapy for 3.7 years to target a glycated hemoglobin
level below 6% reduced 5-year nonfatal myocardial infarc-
tions, but increased 5-year mortality. 
Perspective: The higher risk of death in the intensive-therapy
group would imply that a therapeutic approach that targets
glycated hemoglobin levels below 6% should not be generally
recommended in this population. Further analyses should
explore possible explanations, such as the role of various
drugs, drug combinations, or drug interactions; weight gain;
the relatively short intervention period; and the observed
interaction between the blood pressure and glycemia trials
with respect to mortality.
Summary written by: Debabrata Mukherjee, MD




Association Between Body-Mass Index and Risk of
Death in More Than 1 Million Asians
Zheng W, McLerran DF, Rolland B, et al.
N Engl J Med 2011;364:719-729.
Study Question: Is body mass index (BMI) associated with
increased mortality risk among Asian men and women? 
Methods: Subjects enrolled in 19 studies from Asia were
included in this pooled analysis. Subjects with missing data
on age, BMI, vital status, and age under 18 years were
excluded. Additional exclusion criteria included those with a
BMI over 50 kg/m2. Over 1.1 million adults were followed
over a mean follow-up of 9.2 years. Cox regression models
were used to adjust for potential confounding factors.  A total
of 1,141,609 subjects (535,199 men and 606,410 women)
were included. The overall mean BMI was 22.9 ± 3.6 (range,
19.8-23.7). Approximately 120,700 deaths were recorded
(35.7% from cardiovascular disease, and 29.9% from cancer).
The lowest risk of death was observed among persons with a
BMI range of 22.6-27.5 kg/m2. Risk for death was increased
for those with a BMI under or over that range. For those
with a BMI of 35 kg/m2 or greater, the increased risk was
50%. For subjects with a BMI of 15 kg/m2 or less, the risk of
death ranged from 2.0-2.8%. A similar U-shaped association
was observed between BMI and risk for death from cancer,
cardiovascular disease, and other causes. In cohorts compris-
ing Indians and Bangladeshis, the risk of death from any
cause and from causes other than cancer or cardiovascular dis-
ease was increased among persons with a BMI of 20 kg/m2 or
less, as compared to those with a BMI between 22.6 and 25
kg/m2. No increased risk of death for this group was noted
with a higher BMI. 
Conclusions: Underweight was associated with an increased risk
of death in all Asian populations, and increase in BMI was
associated with an increased risk of death for East Asians, but
not for Indians and Bangladeshis. 
Perspective: This large-scale study suggests that BMI is an
important marker for health; being underweight is a signifi-
cant indicator of increased all-cause mortality. Factors
associated with being underweight may identify opportunities
for intervention. Among those populations with increased
mortality risk associated with increased BMI, a similar analy-
sis will assist public health efforts in areas of preventive care.
Summary written by: Elizabeth A. Jackson, MD
Public Health Importance of Triggers of Myocardial
Infarction: A Comparative Risk Assessment
Nawrot TS, Kunzli N, Munters E, Nemery B.
Lancet 2011;377:732-740.
Study Question: What is the importance and relevance of trig-
gers for myocardial infarction (MI)?  
Methods: Literature from PubMed and the Web of Science
(January 1960 to January 2010) was examined for studies
which identified triggers of nonfatal MI. Data from these
studies were used to calculate population-attributable frac-
tions for MI risk. When feasible, the authors completed a
meta-regression analysis for studies which examined the
same trigger. 
Results: Of the 528 references identified, 36 epidemiological
studies were included. Exposure prevalence for triggers
ranged from 0.04% for cocaine to 100% for air pollution.
The odds ratios ranged from 1.05 to 23.7. Trigger risks for
MI, from highest to lowest, included cocaine, heavy meal,
smoking of marijuana, negative emotions, physical exer-
tion, positive emotions, anger, sexual activity, traffic
exposure, respiratory infections, coffee consumption, and
air pollution. Air pollution as a trigger was based on a dif-
ference of 30 μg/m3 in particulate matter with a diameter
<10 μm (PM10). Accounting for the odds ratio and preva-
lence of exposure, the highest population-attributable
fraction for MI risk was related to traffic exposure (7.4%)
followed by physical exertion (6.2%), alcohol (5.0%), coffee
(5.0%), negative emotions (3.9%), anger (3.1%), heavy meal
(2.7%), positive emotions (2.4%), sexual activity (2.2%),
cocaine use (0.9%), marijuana use (0.8%), and respiratory
infections (0.6%). 
Conclusions: Air pollution is an important risk for MI, given
the magnitude of risk and prevalence in the population.  
Perspective: This well-done analysis demonstrates that risks
which may appear to be small may have significant public
health importance if they are present for significant amounts
of time. These results suggest that reducing exposure to air
pollution could lead to reductions in MI.
Summary written by: Elizabeth A. Jackson, MD
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